R&D Spending Showdown: Bristol-Myers Squibb Company vs Jazz Pharmaceuticals plc

Bristol-Myers vs Jazz: A Decade of R&D Investment

__timestampBristol-Myers Squibb CompanyJazz Pharmaceuticals plc
Wednesday, January 1, 2014453400000085181000
Thursday, January 1, 20155920000000135253000
Friday, January 1, 20164940000000162297000
Sunday, January 1, 20176411000000198442000
Monday, January 1, 20186345000000226616000
Tuesday, January 1, 20196148000000299726000
Wednesday, January 1, 202011143000000335375000
Friday, January 1, 202110195000000505748000
Saturday, January 1, 20229509000000590453000
Sunday, January 1, 20239299000000849658000
Monday, January 1, 202411159000000
Loading chart...

Unleashing the power of data

R&D Investment: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Bristol-Myers Squibb Company and Jazz Pharmaceuticals plc have shown contrasting approaches to R&D investment. From 2014 to 2023, Bristol-Myers Squibb consistently outspent Jazz Pharmaceuticals, with its R&D expenses peaking in 2020 at over 11 billion dollars, a staggering 13 times more than Jazz's highest expenditure in 2023. This significant investment reflects Bristol-Myers Squibb's aggressive strategy to maintain its leadership in the industry. Meanwhile, Jazz Pharmaceuticals has steadily increased its R&D spending, growing by nearly 900% from 2014 to 2023, signaling its ambition to expand its market presence. This showdown highlights the diverse strategies companies employ to drive innovation and secure their future in the ever-evolving pharmaceutical landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025